Individual generic drug information

progesterone

Reference monograph

Part of registered formulation

PROGESTERONE

Reference record: Progesterone
Source: BNF 80 (2020–2021)
Printed source pages: 830, 831
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Progesterone only.

Indications And Dose

CRINONE ® VAGINAL GEL Infertility due to inadequate luteal phase ▶BY VAGINA ▶Adult: 1 applicatorful daily, to be started either after documented ovulation or on day 18–21 of cycle, in vitro fertilisation, daily application continued for 30 days after laboratory evidence of pregnancy CYCLOGEST ® PESSARIES Premenstrual syndrome | Post-natal depression ▶BY VAGINA, OR BY RECTUM ▶Adult: 200–800 mg daily, doses above 200 mg to be given in 2 divided doses, for premenstrual syndrome start on day 12–14 and continue until onset of menstruation (but not recommended); rectally if barrier methods of contraception are used, in patients who have recently given birth or in those who suffer from vaginal infection or recurrent cystitis LUBION ® Supplementation of luteal phase during assisted reproductive technology (ART) treatment in women for whom vaginal preparations are inappropriate ▶BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION ▶Adult: 25 mg once daily from day of oocyte retrieval up to week 12 of pregnancy LUTIGEST ® Luteal support as part of an Assisted Reproductive Technology (ART) treatment programme ▶BY VAGINA ▶Adult: 100 mg 3 times a day, to be started the day after oocyte retrieval, and continued for 30 days once pregnancy is conﬁrmed UTROGESTAN ® CAPSULES Progestogenic opposition of oestrogen HRT ▶BY MOUTH ▶Adult: 200 mg once daily on days 15–26 of each 28-day oestrogen HRT cycle, alternatively 100 mg once daily on days 1–25 of each 28-day oestrogen HRT cycle UTROGESTAN ® VAGINAL CAPSULES Supplementation of luteal phase during assisted reproductive technology (ART) cycles ▶BY VAGINA ▶Adult: 1 capsule 3 times a day from day of embryo transfer until at least week 7 of pregnancy up to week 12 of pregnancy

Source page 830

Contra Indications

Acute porphyrias p. 1120. avoid in patients with a history of liver tumours. breast cancer (unless progestogens are being used in the management of this condition). genital cancer (unless progestogens are being used in the management of this condition). history during pregnancy of idiopathic jaundice. history during pregnancy of pemphigoid gestationis. history during pregnancy of severe pruritus. history of thromboembolism . incomplete miscarriage. missed miscarriage. severe arterial disease. thrombophlebitis. undiagnosed vaginal bleeding

Source page 830

Cautions

Asthma. cardiac dysfunction. conditions that may worsen with ﬂuid retention. diabetes (progestogens can decrease glucose tolerance—monitor patient closely). epilepsy. history of depression. hypertension. migraine. susceptibility to thromboembolism (particular caution with high dose)

Source page 830

National Funding Access Decisions

LUTIGEST ® Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (October 2016) that progesterone (Lutigest ®) is accepted for use within NHS Scotland for luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women. This advice is contingent upon the continuing availability of the Patient Access Scheme (PAS) in NHS Scotland or a list price that is equivalent or lower. LUBION ® Scottish Medicines Consortium (SMC) decisions SMC No. SMC2017 The Scottish Medicines Consortium has advised (July 2018) that progesterone (Lubion ®) is accepted for use within NHS Scotland for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations. UTROGESTAN ® VAGINAL CAPSULES Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (May 2017) that micronised progesterone (Utrogestan Vaginal ®) is accepted for use within NHS Scotland for supplementation of the luteal phase during Assisted Reproductive Technology cycles in women. This advice is contingent upon the continuing availability of the Patient Access Scheme in Scotland or a list price that is equivalent or lower. l LESS SUITABLE FOR PRESCRIBING ▶With vaginal use Progesterone pessaries are less suitable for prescribing.

Source page 831

Safety

Extracted information for Progesterone only.

Side Effects

▶Common or very common ▶With oral use Headache. menstrual cycle irregularities ▶With vaginal use Breast pain. drowsiness. gastrointestinal discomfort ▶Uncommon ▶With oral use Breast pain. constipation. diarrhoea. dizziness. drowsiness. jaundice cholestatic. skin reactions . vomiting ▶Rare or very rare ▶With oral use Depression. nausea ▶Frequency not known ▶With intramuscular use Alopecia. breast changes. cervical abnormalities. depression. drowsiness. fever. hirsutism. insomnia. jaundice cholestatic. menstrual cycle irregularities. nausea. oedema. protein catabolism. skin reactions. weight increased ▶With rectal use Diarrhoea. ﬂatulence ▶With vaginal use Leakage of the pessary base. menstrual cycle irregularities. vulvovaginal pain

Source page 830

Pregnancy

Not known to be harmful.

Source page 830

Breast Feeding

Avoid—present in milk.

Source page 830

Hepatic Impairment

Manufacturer advises caution; avoid in severe impairment. For Utrogestan® oral capsules, manufacturer advises avoid in acute or active liver disease. For Crinone® vaginal gel, manufacturer advises caution in severe impairment.

Source page 830

Renal Impairment

Use with caution.

Source page 830

Dose and formulations

Extracted information for Progesterone only.

Directions For Administration

▶With oral use Capsules should be taken at bedtime on an empty stomach.

Source page 830

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Pessary ▶Cyclogest (L.D. Collins & Co. Ltd) Progesterone 200 mg Cyclogest 200mg pessaries | 15 pessary P £8.95 DT = £8.95 Progesterone 400 mg Cyclogest 400mg pessaries | 15 pessary P £12.96 DT = £12.96 ▶Lutigest (Ferring Pharmaceuticals Ltd) Progesterone 100 mg Lutigest 100mg vaginal tablets | 21 pessary P £19.50 DT = £19.50 Vaginal gel ▶Crinone (Merck Serono Ltd) Progesterone 80 mg per 1 gram Crinone 8% progesterone vaginal gel | 15 unit dose P £30.83 DT = £30.83 Capsule EXCIPIENTS: May contain Arachis (peanut) oil ▶Utrogestan (Besins Healthcare (UK) Ltd) Progesterone 100 mg Utrogestan 100mg capsules | 30 capsule P £5.13 DT = £5.13 Progesterone 200 mg Utrogestan 200mg vaginal capsules with applicators | 21 capsule P £21.00 DT = £21.00 8.1a Anti-oestrogens OVULATION STIMULANTS

Source page 831

Clinical care

Extracted information for Progesterone only.

Patient And Carer Advice

▶With oral use Patient counselling is advised for progesterone capsules (administration).

Source page 830

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

1 applicatorful daily, to be started either after

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

200–800 mg daily, doses above 200 mg to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

25 mg once daily from day of oocyte retrieval up

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

100 mg 3 times a day, to be started the day after

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

200 mg once daily on days 15–26 of each 28-day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

1 capsule 3 times a day from day of embryo

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

progesterone

Reference monograph

Part of registered formulation

PROGESTERONE

Reference record: Progesterone
Source: BNF 80 (2020–2021)
Printed source pages: 830, 831
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Progesterone only.

Indications And Dose

Source page 830

Contra Indications

Source page 830

Cautions

Source page 830

National Funding Access Decisions

Source page 831

Safety

Extracted information for Progesterone only.

Side Effects

Source page 830

Pregnancy

Not known to be harmful.

Source page 830

Breast Feeding

Avoid—present in milk.

Source page 830

Hepatic Impairment

Source page 830

Renal Impairment

Use with caution.

Source page 830

Dose and formulations

Extracted information for Progesterone only.

Directions For Administration

▶With oral use Capsules should be taken at bedtime on an empty stomach.

Source page 830

Medicinal Forms

Source page 831

Clinical care

Extracted information for Progesterone only.

Patient And Carer Advice

▶With oral use Patient counselling is advised for progesterone capsules (administration).

Source page 830

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

1 applicatorful daily, to be started either after

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

200–800 mg daily, doses above 200 mg to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

25 mg once daily from day of oocyte retrieval up

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

100 mg 3 times a day, to be started the day after

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

200 mg once daily on days 15–26 of each 28-day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Adults

First line only; read the complete Indications and dose section above.

1 capsule 3 times a day from day of embryo

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 830

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.